Raymond James analyst Jayson Bedford raised the firm’s price target on Abbott to $123 from $109 and keeps an Outperform rating on the shares. The firm thought Q4 results were "encouraging," and feels the initial guidance for 2023 was appropriate, the analyst tells investors in a research note. Additionally, Raymond James believes Abbott is well-positioned to drive consistent above-peer underlying growth.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott expects $2B in covid testing in FY23
- Abbott Delivers Better-than-Expected Q4 Earnings
- Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
- Abbott CEO says ‘R&D pipeline continues to be highly productive’
- Abbott sees FY23 adjusted EPS $4.30-$4.50, consensus $4.40
